ONO-5046Na + ONO-5046Na
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Community-acquired Pneumonia
Conditions
Community-acquired Pneumonia
Trial Timeline
Dec 1, 2006 → —
NCT ID
NCT00417326About ONO-5046Na + ONO-5046Na
ONO-5046Na + ONO-5046Na is a phase 2 stage product being developed by Ono Pharmaceutical for Community-acquired Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00417326. Target conditions include Community-acquired Pneumonia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00417326 | Phase 2 | Completed |
Competing Products
9 competing products in Community-acquired Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ceftaroline + Ceftriaxone | Pfizer | Phase 3 | 76 |
| Azithromycin microspheres 2.0 single dose | Pfizer | Phase 3 | 76 |
| IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin | Pfizer | Approved | 84 |
| Azithromycin SR | Pfizer | Phase 3 | 76 |
| Azithromycin SR + Amoxiclav | Pfizer | Pre-clinical | 22 |
| tigecycline | Pfizer | Phase 3 | 76 |
| Tigecycline + Levofloxacin | Pfizer | Phase 3 | 76 |
| Omadacycline + Moxifloxacin | Zai Lab | Phase 3 | 72 |
| ceftobiprole medocaril + IV standard-of-care cephalosporin | Basilea Pharmaceutica | Phase 3 | 72 |